(VIANEWS) – Shares of Novavax (NASDAQ Composite: NVAX) rose 5.22% to $205.10 at 10:25 EST on Friday, after five sequential sessions in a row of gains. NASDAQ Composite is dropping 0.77% to $15,063.02, after five sequential sessions in a row of losses. This seems, so far, a somewhat negative trend trading session today.
Novavax’s last close was $194.92, 41.23% under its 52-week high of $331.68.
Today’s last reported volume for Novavax is 2665124 which is 49.87% below its average volume of 5317436.
The company’s growth estimates for the current quarter is a negative 21.8% and positive 213.7% for the next.
Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 1.2B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Novavax’s stock is considered to be oversold (<=20).
Novavax’s Stock Yearly Top and Bottom Value
Novavax’s stock is valued at $205.10 at 10:25 EST, way below its 52-week high of $331.68 and way higher than its 52-week low of $107.08.
Novavax’s Moving Average
Novavax’s worth is way above its 50-day moving average of $170.98 and higher than its 200-day moving average of $193.54.
Previous days news about Novavax (NVAX)
- Novavax: partner takeda submits NDA in Japan for approval of Covid-19 vaccine. According to Business Insider on Thursday, 16 December, "In addition to the submission of the NDA to MHLW in Japan, Novavax and Serum Institute of India Pvt. ", "Additionally, Novavax and SK bioscience announced a Biologics License Application submission to MFDS in South Korea. "
More news about Novavax (NVAX).